Drug Trials

Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia (AML)

Medical News Today (Free subscription) | 11 hours ago

Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its Phase II clinical trial in refractory and relapsed AML with LOR-2040 in combination with cytarabine has been successfully completed to the end-of-stage...

• Lorus Therapeutics Inc.: Lorus Therapeutics Announces Positive Result in Its Phase II Clinical Study of LOR-2040 in Acute Myeloid Leukemia (AML) - Market Wire

Cytokinetics To Present Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference

Medical News Today (Free subscription) | 11 hours ago

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that a poster and oral presentation summarizing non-clinical data regarding CK-2017357, a fast skeletal troponin activator, are scheduled to be presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 at the Princesa Sofia Hotel in Barcelona, Spain.

ArGentis Acquires Rights To Rheumatoid Arthritis Therapy Entering Phase I Clinical Trial

Medical News Today (Free subscription) | yesterday

arGentis Pharmaceuticals, LLC announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients. ARG301 is a synthetic peptide, which in animal studies appears to...

Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

Medical News Today (Free subscription) | 29/11/2009

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

HIV/AIDS Treatment Specific To Each Patient Moves Closer To Reality

Medical News Today (Free subscription) | 27/11/2009

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. Sékaly from the Université de Montréal.

• Customised HIV treatment closer to reality - Sify

Nuclear Medicine And Molecular Imaging Professionals Will Convene In Albuquerque, N.M., Jan. 27-Feb. 2010

Medical News Today (Free subscription) | 26/11/2009

SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.

Synexus Leads The Way In South Africa With Vital Paediatric Vaccines Trial

Medical News Today (Free subscription) | 25/11/2009

UK-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited more than 2000 children aged between 5 and 10 weeks in 3 months, making Synexus the largest single source of subjects for this Phase III...

• Synexus Leads the Way in South Africa with Vital Paediatric Vaccines Trial - Business Wire

Beardsworth(R) Selects OmniComm Systems' TrialMasterTM Solution For The Electronic Data Capture (EDC) Of A Phase II Vaccine Study

Medical News Today (Free subscription) | 25/11/2009

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful...

• OmniComm Systems, Inc.: Beardsworth(R) Selects OmniComm Systems' TrialMaster(TM) Solution for the Electronic Data Capture (EDC) of a Phase II Vaccine Study - Market Wire

Helping Preschoolers To Achieve Asthma Control

Medical News Today (Free subscription) | 25/11/2009

Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal).

Fat Around The Middle Increases The Risk Of Dementia

Medical News Today (Free subscription) | 24/11/2009

Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy. The study has just been published in the scientific journal Neurology. "Anyone carrying a lot of fat around the middle is at greater risk of dying prematurely due to a heart attack or stroke," says Deborah Gustafson, senior...

• Fat Around The Middle Increases Dementia Risk - Red Orbit
• Fat around the middle increases the risk of dementia - Eurekalert
• See the 5 articles on the same subject

Pharmasset: hepatitis C drug trial will continue

Rocky Mount Telegram - Business (Free subscription) | 23/11/2009

NEW YORK — Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical ...

POZEN Announces Start Of Enrollment For PA32540 Phase 3 Program

Medical News Today (Free subscription) | 23/11/2009

POZEN Inc. (NASDAQ: POZN) announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

ImmuPharma Announces Final Results Of PhaseIIb Study Of LUPUZOR™ In Lupus

Medical News Today (Free subscription) | 23/11/2009

ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

Medication Plus Parent Training Improves Behavioral Problems In Children With PDD

Medical News Today (Free subscription) | 23/11/2009

Treatment that includes medication plus a structured training program for parents reduces serious behavioral problems in children with autism and related conditions, according to a study funded by the National Institute of Mental Health (NIMH). The study, which was part of the NIMH Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, was published in the December 2009 issue of the...

• Autism: Parent training complements medication for treating behavioral problems in children with PDD - Science Daily
• Parent Training Complements Medication For Behavioral Problems In Children With PDD - Red Orbit

Immunology Expert At Children's Hospital Receives APS Prize For Patient-oriented Research

Medical News Today (Free subscription) | 23/11/2009

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize for his contributions to research and treatment of inherited immune deficiency diseases. The Judson Daland Prize for Clinical...